Recent News

• 07 April 2026   Press Release

  Chemspace, Enamine, and Paul Scherrer Institute Launch a Joint Service for Fragment-Based Lead Discovery

  Chemspace, a drug discovery engine providing machine learning-guided support for hit identification, hit to lead, and lead optimization using the largest purchasable collection of chemicals and biologics, Enamine, a leading provider of small molecules and drug discovery services, and the Paul Scherrer Institute (PSI), the largest research institute for natural and engineering sciences in Switzerland, have announced today a strategic collaboration aimed at creating an efficient platform for fragment-based drug discovery in the ultra-large chemical space.

• 02 April 2026   Press Release

  Enamine's IDD Platform Accelerates Nuclide Therapeutics' Precision Radiotheranostics Pipeline Towards the Clinic

  Nuclide Therapeutics and Enamine initiated their cooperation in 2025. Since then, Enamine has supported Nuclide Therapeutics in progressing from preclinical evaluation towards IND-enabling studies and first-in-human clinical trials for its lead program focused on first-in-class molecular radiotherapies for therapy-resistant cancers. The relationship proved to be highly productive and innovative, delivering development milestones ahead of schedule with short development cycles and efficient use of resources.

• 24 March 2026   Press Release

  Enamine Joins Agora Open Science Trust and Variational AI to Advance Open-Science Discovery of PRMT6 Inhibitors

  Enamine, a leading integrated drug discovery contract research organization (CRO) has today announced its participation in an open-science collaboration with Variational AI and the Agora Open Science Trust. This initiative aims to advance the discovery of novel small-molecule inhibitors targeting PRMT6, which is a therapeutic target implicated in Spinal and Bulbar Muscular Atrophy (SBMA), a rare neuromuscular disorder currently lacking approved treatments that slow or halt the progression of the disease.